Desjardins Global Asset Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Desjardins Global Asset Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$1.94M	Buy	+15,793	New	+$1.97M	0.21%	116

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.22B AUM 26.01% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Desjardins Global Asset Management's JAZZ Position: Q4 2023 in Review

Desjardins Global Asset Management opened a new position in Jazz Pharmaceuticals (JAZZ) in Q4 2023: 15,793 shares worth $1.94M. The stake represents 0.21% of the portfolio and ranks #116 among its holdings.

499 funds tracked by Wall St. Rank hold JAZZ as of Q4 2023.

Desjardins Global Asset Management held 15,793 shares of Jazz Pharmaceuticals worth $1.94M as of Q4 2023.
Jazz Pharmaceuticals was a new Desjardins Global Asset Management position in Q4 2023.
Jazz Pharmaceuticals made up 0.21% of Desjardins Global Asset Management's portfolio in Q4 2023, its #116 holding.
499 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2023.

Based on Desjardins Global Asset Management's 13F filing for Q4 2023, filed 30 Jan 2024.